Nimenrix (MenACWY-TT) / Pfizer 
Welcome,         Profile    Billing    Logout  
 29 Diseases   10 Trials   10 Trials   298 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nimenrix (MenACWY-TT) / Pfizer
2013-001823-38: Second meningococcal vaccination in Dutch children: Study to compare the tetravalent MenACWY-TT conjugate vaccine with the monovalent MenC-TT conjugate vaccine. Tweede meningokokken vaccinatie bij nederlandse kinderen: Een onderzoek waarbij het tetravelente MenACWY-TT vaccin vergeleken zal worden met het monovalente MenC-TT vaccin.

Ongoing
4
410
Europe
NeisVac-C, Nimenrix, NeisVac-C, Nimenrix, NeisVac-C, Nimenrix, NeisVac-C, Nimenrix
National Institute of Public Health and Environment (RIVM, the Netherlands), National Institute of Public Health and Environment (RIVM, the Netherlands)
The monovalent MenC-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal group C. The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y. Het monovalente MenC-TT vaccine beschermt tegen invasieve meningokokkenziekte van type C. Het tetravalente MenACWY-TT vaccine beschermt tegen invasieve meningokokkenziekte van type A, C, W en Y.
 
 
2014-000967-42: Strengthening memory immunity in the aged population by vaccinating pre-elderly Stimuleren van geheugen immuniteit in de ouder wordende populatie door mensen op middelbare leeftijd te vaccineren

Ongoing
4
250
Europe
Nimenrix, Zostavax, Nimenrix, Zostavax, Nimenrix, Zostavax, Nimenrix, Zostavax
National Institute for Public Health and the Environment (RIVM, Netherlands), National Institute for Public Health and the Environment (RIVM, The Netherlands)
The vaccine administered in this study is used to prevent meningococcal disease caused by the bacteria Neisseria meningitidis group A,C,W,Y (Nimenrix) and Herpes Zoster disease caused by the Varicella zoster virus (Zostavax). The vaccinaties toegediend in de studie worden gebruikt om meningokokkenziekte veroorzaakt door Neisseria meningitidis groep A,C,W,Y (Nimenrix) en Herpes Zoster veroorzaakt door het herpes zoster virus (Zostavax) te voorkomen.
 
 
2016-002381-31: follow up of participants in a previous study of quadrivalent meningitis vaccine.

Ongoing
4
93
Europe
Menveo, Nimenrix, Powder and solvent for solution for injection in pre-filled syringe, Menveo, Nimenrix
Public Health England, Department of Health Policy Research Programme
No specific medical condition(s) - responses to vaccination against meningococcal disease., Vaccination against different types of bacteria that cause meningitis., Body processes [G] - Immune system processes [G12]
 
 
2019-001301-24: Study to investigate the immune response and determine functional antibodies after a MenACWY-vaccination Studie naar de werkzaamheid van een MenACWY-vaccinatie bij volwassenen van 65 jaar en ouder

Not yet recruiting
4
140
Europe
Nimenrix, Powder and solution for solution for injection, Nimenrix
National Institute for Public Health and the Environment (RIVM), National Institute for Public Health and the Environment (RIVM)
The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y. Het tetravalente MenACWY-TT vaccin beschermt tegen invasieve meningokokkenziekte van type A, C, W en Y., Invasive meningococcal disease, meningitis, sepsis Invasieve meningokokkenziekte, hersenvliesontsteking, bloedvergiftiging, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05929651: Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Recruiting
4
180
RoW
MenACYW conjugate vaccine, MenQuadfi®
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
09/24
09/24
2020-004385-19: Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria

Ongoing
3
165
Europe
iptacopan, LNP023, Capsule, hard, PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, Nimenrix, HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood disorder, Diseases [C] - Immune System Diseases [C20]
 
 
2020-005059-19: A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE Vaiheen 3b kahdella Nimenrix-annoksella tehty avoin tutkimus vauvoilla

Not yet recruiting
3
150
Europe
Powder and solution for solution for injection, Nimenrix®
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, Pfizer Inc.
Invasive Meningococcal Disease (IMD), Prevention of disease caused by a type of bacteria called NeisseriaI, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05093829: Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Active, not recruiting
3
1325
RoW
NmCV-5, MenACWY-TT, Nimenrix
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis
03/23
07/25
NCT03547271 / 2017-004731-36: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Hourglass Jan 2023 - Dec 2023 : Data from trial for meningococcal infections
Completed
3
1660
Europe, RoW
MenACYW conjugate vaccine, MenQuadfi®, Meningococcal group A, C, W-135, and Y conjugate vaccine, Nimenrix®, DTaP-IPV-HB-Hib vaccine, Hexyon®/Hexacima®, Pneumococcal vaccine (13-valent), Prevenar 13®, Pneumococcal vaccine (10-valent), Synflorix®, MMR vaccine, M-M-RVAXPRO®
Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
05/23
05/23
NCT06284915: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Recruiting
3
840
Europe, RoW
MenACYW conjugate vaccine, MenQuadfi®, Nimenrix®
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
03/25
03/25
NCT04400838 / 2020-001228-32: Investigating a Vaccine Against COVID-19

Active, not recruiting
2/3
12390
Europe
ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, Menveo, Nimenrix, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost, Two dose MenACWY vaccine, ChAdOx1 nCoV-19 (qPCR), ChAdOx1 nCoV-19 0.5mL prime plus boost, Two dose MenACWY vaccine min. 4 weeks apart, Two dose ChAdOx1 nCoV-19/Covishield 0.5mL, Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL
University of Oxford
Coronavirus
03/24
03/24
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25
NCT05743881: A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Recruiting
1
310
Europe, Canada, US, RoW
mRNA-1345, mRNA-1365, Placebo, Nimenrix
ModernaTX, Inc.
Respiratory Syncytial Virus, Human Metapneumovirus
07/26
07/26

Download Options